Patients could soon be reimbursed for ineffective anti-obesity drugs after human omics company Ovation and precision medicine company PrecisionLife partnered to develop a first-of-its-kind test. The collaboration between the companies aims to develop drug-response biomarkers for glucagon-like peptide-1 receptor agonist (GLP-1) therapies. The resulting findings could form the basis… Read More
This is the latest episode of the free DDW narrated podcast, titled “Innovative uses for biomarkers in drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Advances in neuroscience drug discovery”, “Putting human data at the centre of… Read More
PrecisionLife and Metrodora Foundation have successfully reproduced the genetic risk factors associated with long Covid across US and UK patient populations with diverse ancestries. The landmark study represents a significant step forward in understanding the genetic underpinnings of long Covid and offers… Read More
PrecisionLife and the Nucleic Acid Therapy Accelerator (NATA) have announced a collaboration to co-develop novel oligonucleotide therapies for sporadic motor neurone disease/ALS. The collaboration combines NATA’s expertise in NAT design and optimisation with PrecisionLife’s understanding of complex disease biology and the mechanisms, drug targets and treatments… Read More
Listen to this article on the DDW Podcast: Dr Steve Gardner, CEO of the computational biology company PrecisionLife, explores the challenges of achieving precision medicine in complex CNS conditions and explains how new precision neuroscience approaches are benefitting pharmaceutical companies who are again investing in… Read More
PrecisionLife and the Metrodora Institute have agreed a partnership to jumpstart the diagnosis and treatment options for a range of complex, chronic diseases. The diseases include long Covid, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), amyotrophic lateral sclerosis (ALS), Sjögren’s syndrome, and many more. The partners… Read More
PrecisionLife and the University of Oxford have signed a data access agreement to license the Oxford Endometriosis Gene (OXEGENE) dataset to develop new personalised treatments for endometriosis patients. Endometriosis affects 10% of women globally, but on average it takes over seven years for patients to receive… Read More
PrecisionLife and Nanopharmaceutics have entered a strategic collaboration aiming to accelerate and de-risk the development of Nanopharmaceutics’ portfolio of central nervous system (CNS) assets. This collaboration between PrecisionLife and Nanopharmaceutics uses mechanistic patient stratification biomarkers to inform clinical trial design and transform the lives of patients. … Read More
Not-for-profit medical research organisation LifeArc and techbio company PrecisionLife have agreed a strategic R&D collaboration to accelerate the discovery of targeted treatments for motor neurone disease (MND). MND is also known as amyotrophic lateral sclerosis (ALS) and Lou Gehrig’s disease. The collaboration will accelerate… Read More
